Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 08 04:00PM ET
59.41
Dollar change
-0.51
Percentage change
-0.85
%
IndexS&P 500 P/E- EPS (ttm)-2.27 Insider Own1.79% Shs Outstand181.00M Perf Week1.16%
Market Cap10.69B Forward P/E34.92 EPS next Y1.70 Insider Trans-0.73% Shs Float178.26M Perf Month-2.14%
Income-413.00M PEG- EPS next Q0.14 Inst Own90.39% Short Float4.67% Perf Quarter-0.45%
Sales4.42B P/S2.42 EPS this Y342.00% Inst Trans-6.30% Short Ratio4.99 Perf Half Y6.45%
Book/sh19.52 P/B3.04 EPS next Y53.96% ROA-4.19% Short Interest8.32M Perf Year74.27%
Cash/sh1.86 P/C31.92 EPS next 5Y12.00% ROE-11.19% 52W Range32.38 - 61.20 Perf YTD32.23%
Dividend Est.- P/FCF108.00 EPS past 5Y- ROI-4.90% 52W High-2.92% Beta1.15
Dividend TTM- Quick Ratio1.96 Sales past 5Y12.75% Gross Margin21.82% 52W Low83.48% ATR (14)0.54
Dividend Ex-Date- Current Ratio2.51 EPS Y/Y TTM58.57% Oper. Margin3.51% RSI (14)48.05 Volatility0.98% 0.78%
Employees16900 Debt/Eq1.40 Sales Y/Y TTM4.39% Profit Margin-9.34% Recom3.10 Target Price63.42
Option/ShortYes / Yes LT Debt/Eq1.38 EPS Q/Q83.10% Payout- Rel Volume1.54 Prev Close59.92
Sales Surprise-3.34% EPS Surprise-387.61% Sales Q/Q4.18% EarningsNov 05 BMO Avg Volume1.67M Price59.41
SMA20-0.17% SMA50-0.95% SMA2003.12% Trades Volume2,565,304 Change-0.85%
Date Action Analyst Rating Change Price Target Change
Nov-16-23Upgrade Robert W. Baird Neutral → Outperform $45 → $53
Sep-05-23Upgrade Argus Hold → Buy $62
Jul-20-23Initiated Wells Fargo Equal Weight $43
Jul-05-23Resumed JP Morgan Neutral $45
Jun-14-23Downgrade Jefferies Buy → Hold $45 → $44
May-22-23Downgrade JP Morgan Overweight → Neutral $90 → $45
May-15-23Downgrade Deutsche Bank Buy → Hold $55 → $29
May-08-23Downgrade BofA Securities Neutral → Underperform $28
Apr-17-23Downgrade Robert W. Baird Outperform → Neutral $82 → $53
Apr-14-23Downgrade William Blair Outperform → Mkt Perform
Nov-05-24 03:12PM
08:25AM
08:25AM
07:25AM
07:23AM
07:00AM Loading…
07:00AM
Nov-04-24 03:01AM
Oct-30-24 06:05AM
03:46AM
Oct-23-24 07:05PM
07:45AM
04:40AM
Oct-21-24 07:30AM
07:00AM
Oct-17-24 02:03PM
06:39AM Loading…
Oct-14-24 06:39AM
06:00AM
Oct-10-24 08:03AM
Sep-17-24 09:31AM
Sep-12-24 12:00PM
Sep-07-24 01:05AM
Sep-03-24 02:52PM
Aug-30-24 05:32PM
Aug-29-24 08:45AM
08:07AM
07:49AM
07:30AM
Aug-09-24 09:10AM
Aug-07-24 08:42AM
Jul-16-24 12:28PM
02:00AM Loading…
02:00AM
Jul-01-24 08:00AM
Jun-21-24 05:05PM
01:00PM
Jun-11-24 01:13PM
Jun-07-24 11:30AM
Jun-06-24 10:00AM
May-29-24 09:07AM
May-27-24 03:02AM
May-16-24 02:26PM
May-14-24 10:33AM
May-13-24 11:46AM
11:20AM
May-09-24 01:31PM
01:05AM
12:53AM
May-08-24 11:37PM
07:30PM
06:24PM
04:15PM
May-03-24 10:12AM
09:50AM
08:58AM
08:36AM
08:16AM
04:17AM
04:02AM
May-02-24 01:08PM
11:31AM
08:19AM
08:02AM
06:18AM
Apr-17-24 08:19PM
Apr-16-24 09:53AM
Apr-11-24 02:21AM
Apr-10-24 11:03PM
Apr-08-24 06:31AM
06:28AM
05:55AM
Apr-05-24 11:08PM
Mar-28-24 01:15PM
Mar-11-24 12:44PM
Mar-09-24 01:00PM
Mar-08-24 07:11AM
Mar-07-24 10:41AM
10:31AM
08:00AM
Feb-27-24 10:50AM
Feb-14-24 04:43PM
Feb-13-24 12:32AM
Feb-10-24 09:53AM
Feb-09-24 11:28AM
09:30AM
09:13AM
08:37AM
08:14AM
08:11AM
08:03AM
07:59AM
Feb-08-24 06:37AM
05:48AM
04:53AM
Feb-07-24 12:55PM
12:23PM
11:53AM
07:51AM
Feb-06-24 05:23PM
02:44PM
12:22PM
11:13AM
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferraro Joseph AnthonySVP, General Counsel, CCOOct 18 '24Sale59.9732019,19023,967Oct 21 11:30 AM
Ferraro Joseph AnthonyOfficerOct 18 '24Proposed Sale59.9732019,191Oct 18 03:45 PM
Hawkeswood Thomas WOfficerOct 16 '24Proposed Sale60.5762537,856Oct 16 03:41 PM
McErlane DavidGroup President, BiologicsSep 26 '24Sale59.971,994119,58036,304Sep 27 12:01 PM
McErlane DavidOfficerSep 26 '24Proposed Sale59.982,168130,026Sep 26 03:20 PM
Hopson RickyPres. BioProduct Delivery, CoSAug 02 '24Sale59.5666239,42929,974Aug 05 12:55 PM
Gunther ScottSVP, Quality & Reg. AffairsAug 02 '24Sale59.5566639,66039,635Aug 05 12:51 PM
Ferraro Joseph AnthonySVP, General Counsel, CCOAug 02 '24Sale59.5860836,22524,287Aug 05 12:45 PM
Evoli LisaSVP, Chief HR OfficerAug 02 '24Sale59.673,859230,26739,366Aug 05 12:39 PM
Gennadios AristipposGroup Pres. Pharma & ConsumerAug 02 '24Sale59.551,16969,614113,724Aug 05 12:33 PM
Gunther ScottOfficerAug 05 '24Proposed Sale58.9855432,675Aug 05 11:52 AM
Evoli LisaOfficerAug 02 '24Proposed Sale59.123,895230,274Aug 02 03:37 PM
Gunther ScottOfficerAug 02 '24Proposed Sale59.5566639,660Aug 02 03:34 PM
Hopson RickyOfficerAug 02 '24Proposed Sale59.5666239,427Aug 02 03:28 PM
Gennadios AristipposOfficerAug 02 '24Proposed Sale59.551,16969,609Aug 02 03:27 PM
Hawkeswood Thomas WOfficerAug 02 '24Proposed Sale59.6841324,649Aug 02 03:22 PM
Ferraro Joseph AnthonyOfficerAug 02 '24Proposed Sale59.5860836,225Aug 02 03:13 PM
Maselli AlessandroPresident & CEOJul 29 '24Sale58.769,088534,011177,521Jul 30 04:53 PM
Hopson RickyPres. BioProduct Delivery, CoSJul 29 '24Sale58.6720612,08630,636Jul 30 04:45 PM
Gunther ScottSVP, Quality & Reg. AffairsJul 29 '24Sale58.6928316,60940,301Jul 30 04:39 PM
Gennadios AristipposGroup Pres. Pharma & ConsumerJul 29 '24Sale58.7034920,486114,893Jul 30 04:30 PM
Gunther ScottOfficerJul 30 '24Proposed Sale58.9423513,851Jul 30 11:47 AM
Hawkeswood Thomas WOfficerJul 29 '24Proposed Sale58.8321712,766Jul 29 04:22 PM
Gennadios AristipposOfficerJul 29 '24Proposed Sale58.7034920,487Jul 29 03:34 PM
Hopson RickyOfficerJul 29 '24Proposed Sale58.6720612,087Jul 29 03:20 PM
Maselli AlessandroOfficerJul 29 '24Proposed Sale58.769,088534,034Jul 29 03:18 PM
Gunther ScottOfficerJul 29 '24Proposed Sale58.6928316,609Jul 29 03:13 PM
Masanovich MattiSVP, Chief Financial OfficerJul 08 '24Sale56.742,993169,82333,871Jul 10 04:56 PM
Hopson RickyPres. BioProduct Delivery, CoSJun 04 '24Sale54.261,40176,02320,617Jun 05 09:35 PM
Gunther ScottSVP, Quality & Reg. AffairsMar 15 '24Sale56.2038721,74929,506Mar 19 01:38 PM